Plasma G-CSF levels are predictive of lack of response to zoledronic acid treatment in reducing breast cancer recurrence.

被引：0
|
作者：
Ubellacker, Jessalvn M. [1 ]
Baryawno, Ninib [2 ,3 ]
Severe, Nicolas [2 ,3 ]
DeCristo, Molly J. [1 ]
Sceneay, Jaclyn [4 ]
Haider, Marie-Therese [5 ]
Rhee, Catherine S. [2 ,3 ]
Qin, Yuanbo [4 ]
Holen, Ingunn [5 ]
Gregory, Walter M. [6 ]
Brown, Janet E. [7 ]
Coleman, Robert E. [7 ]
Scadden, David T. [2 ,3 ]
McAllister, Sandra S. [4 ]
机构：
[1] Harvard Med Sch, Dept Med, Boston, MA USA
[2] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[5] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England
[6] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England
[7] Univ Sheffield, Weston Pk Hosp, Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
来源：
MOLECULAR CANCER RESEARCH | 2018年 / 16卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B13
引用
收藏
页码：68 / 69
页数：2
相关论文
共 36 条
  • [21] Defendor Special: Primary empegfilgrastim prophylaxis (prolonged G-CSF) for optimal treatment outcomes in high risk early breast cancer cohort. The interim analysis
    Sorokina, Irina
    Ganshina, Inna
    Ibragimova, Tansuly
    Bondareva, Irina
    Zhukova, Lyudmila
    CANCER RESEARCH, 2023, 83 (05)
  • [22] The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE)
    Facchini, G.
    Caraglia, M.
    Santini, D.
    Nasti, G.
    Ottaiano, A.
    Striano, S.
    Maiolino, P.
    Ruberto, M.
    Fiore, F.
    Tonini, G.
    Budillon, A.
    Laffaioli, R. V.
    Zeppetella, G. L.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2007, 26 (03) : 307 - 312
  • [23] Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+breast cancer.
    Zhukova, Lyudmila
    Ibragimova, Tansylu
    Ganshina, Inna
    Filonenko, Daria
    Sorokina, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] L-folinic acid (FA), fluorouracil (FU), escalating doses of mitoxantrone (N), ciclophosphamide (C) and G-CSF in advanced breast cancer patients (ABC). A phase II study
    Giotta, F
    Romito, S
    Gebbia, V
    Pacillo, G
    Durini, E
    Pezzella, G
    Caruso, M
    Gebbia, N
    Colucci, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 379 - 379
  • [25] HIGH-DOSE EPIRUBICIN AND R-MET-HU G-CSF (FILGRASTIM) IN THE TREATMENT OF PATIENTS WITH ADVANCED BREAST-CANCER - A HELLENIC COOPERATIVE ONCOLOGY GROUP-STUDY
    FOUNTZILAS, G
    SKARLOS, D
    KATSOHIS, C
    PAVLIDIS, N
    GIANNAKAKIS, T
    BAFALOUKOS, D
    FAHANTIDIS, E
    KLOUVAS, G
    BEER, M
    KOSMIDIS, P
    MEDICAL AND PEDIATRIC ONCOLOGY, 1995, 24 (01): : 23 - 28
  • [26] ESCALATING DOSES OF MITOXANTRONE WITH GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) RESCUE PLUS 5-FLUOROURACIL AND HIGH-DOSE LEVOFOLINIC ACID IN METASTATIC BREAST-CANCER
    GEBBIA, V
    VALENZA, R
    TESTA, A
    CANNATA, G
    VERDERAME, F
    GEBBIA, N
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (11) : 1734 - 1736
  • [27] Axillary response and outcome in breast cancer patients after neoadjuvant treatment: The role of radiotherapy in reducing recurrence in ypN0 patients with initially cN plus stage
    Ren, Xiaoqiu
    Yu, Yaner
    Liu, Lihong
    Xia, Wenjie
    Ni, Runliang
    Wei, Shumei
    Wu, Jun
    Wei, Qichun
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer-Further observations from the IMPACT solid study
    Maenpaa, Johanna
    Varthalitis, Ioannis
    Erdkamp, Frans
    Trojan, Andreas
    Krzemieniecki, Krzysztof
    Lindman, Henrik
    Bendall, Kate
    Vogl, Florian D.
    Verma, Shailendra
    BREAST, 2016, 25 : 27 - 33
  • [29] Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
    Di Cosimo, Serena
    Appierto, Valentina
    Pizzamiglio, Sara
    Tiberio, Paola
    Iorio, Marilena, V
    Hilbers, Florentine
    de Azambujas, Evandro
    de la Pena, Lorena
    Izquierdo, Miguel
    Huober, Jens
    Baselga, Jose
    Piccart, Martine
    de Braud, Filippo G.
    Apolone, Giovanni
    Verderio, Paolo
    Daidone, Maria Grazia
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3887 - 3895
  • [30] Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO
    Di Cosimo, S.
    Appierto, V.
    Tiberio, P.
    Verderio, P.
    Pizzamiglio, S.
    Bottelli, S.
    Iorio, M.
    Baselga, J.
    Piccart, M.
    Huober, J.
    Brase, J.
    de la Pena, L.
    Fumagalli, D.
    de Azambuja, E.
    de Braud, F.
    Daidone, M. G.
    CANCER RESEARCH, 2017, 77
1234